



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 15/32	A1	(11) International Publication Number: WO 99/59647 (43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: PCT/US99/10952 (22) International Filing Date: 19 May 1999 (19.05.99) (30) Priority Data: 60/085,931 19 May 1998 (19.05.98) US (71) Applicant (for all designated States except US): THE AMERICAN NATIONAL RED CROSS [US/US]; 430 17th Street, N.W., Washington, DC 20006 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MACPHEE, Martin, J. [CA/US]; 9971 Lake Landing Road, Gaithersburg, MD 20886 (US). DROHAN, William, N. [US/US]; 8417 Oakford Drive, Springfield, VA 22156 (US). BEALL, Dawson [US/US]; 12539 Great Park Circle #101, Germantown, MD 20876 (US). FRIEDMAN, Stanley, A. [US/US]; 4317 Regalwood Terrace, Burtonsville, MD 20866 (US). TUTHILL, David [US/US]; 510 Elm Street, Frederick, MD 21701 (US). BAYER, Valdislav [-/US]; 36 Pontiac Way, Gaithersburg, MD 20878 (US). (74) Agents: GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HEMOSTATIC SANDWICH BANDAGE (57) Abstract <p>The present invention relates to a haemostatic multilayer bandage that comprises preferably a thrombin layer between two fibrinogen layers. The dressing may contain other resorbable materials such as glycolic acid or lactic acid based polymers or copolymers. The inventive haemostatic sandwich bandage is useful for the treatment of wounded tissue.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakistan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HEMOSTATIC SANDWICH BANDAGE

I. FIELD OF THE INVENTION

The present invention relates to a hemostatic sandwich bandage which comprises a plurality of layers that contain resorbable materials and/or coagulation proteins. The inventive
5 hemostatic sandwich bandage is useful for the treatment of wounded tissue.

II. BACKGROUND OF THE INVENTION

The control of hemorrhage (bleeding) is a critical step in first aid and field trauma care. Unfortunately, the materials and methods available to stop bleeding in prehospital care (gauze dressings, direct pressure, and tourniquets) have not changed greatly in the past 2000 years. L.
10 Zimmerman *et al.*, *Great Ideas in the History of Surgery* (San Francisco, Calif: Norman Publishing; 1993), 31. Even in good hands they are not uniformly effective, and the occurrence of excessive bleeding or fatal hemorrhage from an accessible site is not uncommon. J.M. Rocko *et al.*, *J. Trauma* 22:635 (1982).

Mortality data from Vietnam indicates that 10% of combat deaths were due to
15 uncontrolled extremity hemorrhage. *SAS/STAT Users Guide*, 4th ed. (Cary, NC: SAS Institute Inc; 1990). Up to one third of the deaths from exsanguination during the Vietnam War could have been prevented by the use of effective field hemorrhage control methods. *SAS/STAT Users Guide*, 4th ed. (Cary, NC: SAS Institute Inc; 1990).

Although civilian trauma mortality statistics do not provide exact numbers for prehospital
20 deaths from extremity hemorrhage, case and anecdotal reports indicate similar occurrences. J.M. Rocko *et al.*, *J. Trauma* 22:635 (1982). These data suggest that a substantial increase in survival can be effected by the prehospital use of a simple and effective method of hemorrhage control.

Liquid fibrin sealants have been used for years as an operating room adjunct for hemorrhage control. J.L. Garza *et al.*, *J. Trauma* 30:512-513 (1990); H.B. Kram *et al.*, *J. Trauma* 30:97-101 (1990); M.G. Ochsner *et al.*, *J. Trauma* 30:884-887 (1990); T.L. Matthew *et al.*, *Ann. Thorac. Surg.* 50:40-44 (1990); H. Jakob *et al.*, *J. Vasc. Surg.*, 1:171-180 (1984).

- 5 The first mention of tissue glue used for hemostasis dates back to 1909. *Current Trends in Surgical Tissue Adhesives: Proceedings of the First International Symposium on Surgical Adhesives*, M.J. MacPhee *et al.*, eds. (Lancaster, Pa: Technomic Publishing Co; 1995). The widespread use of fibrinogen and thrombin was common in the last year of World War II, but was abandoned because of the transmission of hepatitis. D.B. Kendrick, *Blood Program in WW II*
10 (Washington, DC: Office of the Surgeon General, Department of Army; 1989), 363-368.

- Currently, single donor fibrin sealants are widely used clinically, not only for hemorrhage control but in various surgical situations. W.D. Spotnitz, *Thromb. Haemost.* 74:482-485 (1995); R. Lerner *et al.*, *J. Surg. Res.* 48:165-181 (1990). Even more extensive use is limited by the strict requirements for temperature control, availability of thawed blood components, and the need for
15 mixing of components. Additional problems with the standard fibrin sealants stem from the transfusion risk of human cryoprecipitate (E.M. Soland *et al.*, *JAMA* 274:1368-1373 (1995)), the low and variable amounts of fibrinogen in the cryoprecipitate (10-30 mg) (P.M. Ness *et al.*, *JAMA* 241:1690-1691 (1979)), hypotensive responses to bovine thrombin (R. Berguer *et al.*, *J. Trauma* 31:408-411 (1991)) and antibody responses to bovine thrombin (S.J. Rapaport *et al.*,
20 *Am. J. Clin. Pathol.* 97:84-91 (1992)).

The American Red Cross and others have developed plasma protein purification methods that seem to eliminate the hepatitis risk. R.F. Reiss *et al.*, *Trans. Med. Rev.* 10:85-92 (1996). These products are presently being considered for approval by the Food and Drug Administration.

A dry fibrinogen-thrombin dressing (TACHOCOMB, Hafslund Nycomed Pharma, Linz, Austria) is also available for operating room use in many European countries. U. Schiele *et al.*, *Clin. Materials* 9:169-177 (1992). Present formulations of this dressing use bovine thrombin. While this fibrinogen-thrombin dressing requires no premixing and is easy to use, its utility for field applications is limited by a requirement for storage at 4°C and the necessity for prewetting with saline solution prior to application to the wound.

III. SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide a hemostatic sandwich bandage that can be used for wound healing. Other objects, features and advantages of the present invention will be set forth in the detailed description of preferred embodiments that follows, and in part will be apparent from the description or may be learned by practice of the invention. These objects and advantages of the invention will be realized and attained by the compositions and methods particularly pointed out in the written description and claims hereof.

In accordance with these and other objects, a first embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a first fibrinogen layer; (ii) a thrombin layer adjacent to the first fibrinogen layer; and (iii) a second fibrinogen layer adjacent to the thrombin layer.

A second embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a resorbable material layer; (ii) a first fibrinogen layer adjacent to the resorbable material layer; (iii) a thrombin layer adjacent to the first fibrinogen layer; and (iv) a second fibrinogen layer adjacent to the thrombin layer.

A third embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a first fibrinogen layer; (ii) a resorbable material layer adjacent to the first fibrinogen layer; (iii) a thrombin layer adjacent to the resorbable material layer; and (iv) a second fibrinogen layer adjacent to the thrombin layer.

5 A fourth embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded in a patient which comprises: (i) a resorbable material layer; and (ii) a thrombin layer adjacent to the resorbable material layer. The resorbable material layer may also optionally contain fibrinogen.

10 A fifth embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded in a patient which comprises: (i) a first resorbable material layer; (ii) a second resorbable material layer adjacent to the first resorbable material layer; and (iii) a thrombin layer adjacent to the second resorbable material layer. The resorbable material layers may also optionally contain fibrinogen.

15 Each layer of the inventive hemostatic bandages may also optionally contain one or more suitable fillers, binding agents and/or solubilizing agents. In addition, each of the inventive hemostatic bandages may also optionally further comprise a release layer which contains a release agent and/or a backing material.

20 A sixth embodiment of the present invention is directed to methods for treating wounded tissue in a patient, which comprises applying any of the inventive hemostatic sandwich bandages to the wounded tissue.

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are intended to provide further explanation of the invention as claimed.

IV. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All
5 patents and publications mentioned herein are incorporated by reference.

"Patient" as used herein refers to human or animal individuals in need of medical care and/or treatment.

"Wound" as used herein refers to any damage to any tissue of a patient that results in the loss of blood from the circulatory system. The tissue may be an internal tissue, such as an organ
10 or blood vessel, or an external tissue, such as the skin. The loss of blood may be internal, such as from a ruptured organ, or external, such as from a laceration. A wound may be in a soft tissue, such as an organ, or in hard tissue, such as bone. The damage may have been caused by any agent or source, including traumatic injury, infection or surgical intervention.

"Resorbable material" as used herein refers to a material that is broken down
15 spontaneously and/or by the mammalian body into components which are consumed or eliminated in such a manner as not to interfere significantly with wound healing and/or tissue regeneration, and without causing any significant metabolic disturbance.

"Stability" as used herein refers to the retention of those characteristics of a material that determine activity and/or function.

20 "Binding agent" as used herein refers to a compound or mixture of compounds that improves the adherence of one layer of the inventive hemostatic sandwich bandage to one or more different layers and/or the adherence of the components of a given layer to other components of that layer.

"Solubilizing agent" as used herein refers to a compound or mixture of compounds that improves the dissolution of a protein or proteins in aqueous solvent.

"Filler" as used herein refers to a compound or mixture of compounds that provide bulk and/or porosity to one or more layers of the inventive hemostatic sandwich bandages.

5 "Release agent" as used herein refers to a compound or mixture of compounds that facilitates removal of an inventive hemostatic sandwich bandage from a manufacturing mold.

"Foaming agent" as used herein refers to a compound or mixture of compounds that produces gas when hydrated under suitable conditions.

B. PREFERRED EMBODIMENTS

10 A first preferred embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a first fibrinogen layer; (ii) a thrombin layer adjacent to the first fibrinogen layer; and (iii) a second fibrinogen layer adjacent to the thrombin layer.

15 A second embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a resorbable material layer; (ii) a first fibrinogen layer adjacent to the resorbable material layer; (iii) a thrombin layer adjacent to the first fibrinogen layer; and (iv) a second fibrinogen layer adjacent to the thrombin layer.

20 A third embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded tissue in a patient which comprises: (i) a first fibrinogen layer; (ii) a resorbable material layer adjacent to the first fibrinogen layer; (iii) a thrombin layer adjacent to the resorbable material layer; and (iv) a second fibrinogen layer adjacent to the thrombin layer.

A fourth embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded in a patient which comprises: (i) a resorbable material layer; and (ii) a thrombin layer adjacent to the resorbable material layer. The resorbable material layer may also optionally contain fibrinogen.

5 A fifth embodiment of the present invention is directed to a hemostatic sandwich bandage for treating wounded in a patient which comprises: (i) a first resorbable material layer; (ii) a second resorbable material layer adjacent to the first resorbable material layer; and (iii) a thrombin layer adjacent to the second resorbable material layer. The resorbable material layers may also optionally contain fibrinogen.

10 Each layer of the inventive hemostatic sandwich bandages may also optionally contain one or more suitable fillers, such as sucrose.

Each layer of the inventive hemostatic sandwich bandages may also optionally contain one or more suitable binding agents, such as sucrose.

Each layer of the inventive hemostatic sandwich bandages may also optionally contain one
15 or more suitable solubilizing agents, such as sucrose.

Each layer of the inventive hemostatic sandwich bandages may also optionally contain one or more suitable foaming agents, such as a mixture of citric acid and sodium bicarbonate.

Each of the inventive hemostatic sandwich bandages may also optionally further comprise a release layer which contains a release agent. A preferred release agent is sucrose.

20 Each of the inventive hemostatic sandwich bandages may also further comprise a backing material on the side of the bandage opposite the wound-facing side. The backing material may be affixed with a physiologically-acceptable adhesive or may be self-adhering (*e.g.* by having a sufficient surface static charge). The backing material may be a resorbable material or a non-

resorbable material, such as a silicone patch or plastic. Preferably, the backing material is a resorbable material.

The fibrinogen employed in the inventive hemostatic sandwich bandage is preferably Topical Fibrinogen Complex (TFC), but any suitable fibrinogen, or derivative or metabolite thereof (such as fibrinopeptide A and fibrinopeptide B), may be employed as desired. A specific fibrinogen (or fibrinogen-containing composition) for a particular application may be selected empirically by one skilled in the art. The fibrinogen may also contain Factor XIII.

TFC is a mixture of human plasma proteins which have been purified to an appropriate level and virally inactivated. A preferred aqueous solution of TFC contains 100-130 mg/mL total protein, of which at least 80% is fibrinogen. Other constituents of TFC include albumin (generally about 5-25 mg/mL); plasminogen (generally about 5 mg/mL); Factor XIII (generally about 10-40 Units/mL); and polysorbate 80 (no more than 3%). The pH of TFC is generally in the range of 7.1-7.5. Suitable TFC may also contain fibronectin.

The thrombin employed in the inventive hemostatic bandage is preferably a lyophilized mixture of human plasma proteins which have been purified to an appropriate level and virally inactivated. A preferred aqueous solution of thrombin contains thrombin at a potency of about 300 ± 50 International Units/mL. Other constituents include albumin (generally about 5 mg/mL) and glycine (generally about 0.3 M \pm 0.05M). The pH of the preferred thrombin is generally in the range of 6.5-7.1.

Additionally, in each of the embodiments of the present invention, thrombin may be replaced by any of the agents known by those skilled in the art to be activators of fibrin formation. Illustrative examples of such agents are snake venoms. A specific activator of fibrin formation for a particular application may be selected empirically by one skilled in the art.

Any suitable resorbable material known to those skilled in the art may be employed in the present invention. For example, the resorbable material may be a proteinaceous substance, such as silk, fibrin, keratin, collagen and/or gelatin, or a carbohydrate substances, such as alginates, chitin, cellulose, proteoglycans (*e.g.* poly-N-acetyl glucosamine), glycolic acid polymers, lactic acid polymers, or glycolic acid/lactic acid co-polymers. Specific resorbable material(s) for a particular application may be selected empirically by those skilled in the art.

Preferably, the resorbable material is a carbohydrate substance. Illustrative examples of particularly preferred resorbable materials are sold under the tradenames VICRYL and DEXXON.

10 The various layers of the inventive hemostatic sandwich bandage may be affixed to one another by any suitable means known and available to those skilled in the art. Preferably, the fibrinogen layer(s) and/or the thrombin layer(s) is (are) applied as a series of quick-frozen aqueous solution layers and subsequently lyophilized or freeze-dried.

In a particularly preferred embodiment of the present invention, when the inventive
15 bandages are prepared using a mold, a release agent, such as sucrose, is applied to the mold before the first layer of the bandage being prepared. In such embodiments, the inventive hemostatic sandwich bandage further comprises a release layer, which contains said release agent, adjacent to the (i) layer and on the opposite side from the (ii) layer.

Alternatively, a physiologically-acceptable adhesive may applied to the resorbable material
20 and/or the backing material (when present) and the fibrinogen layer(s) and/or the thrombin layer(s) subsequently affixed thereto.

In one embodiment of the inventive sandwich bandage, the physiologically-acceptable adhesive has a shear strength and/or structure such that the resorbable material and/or backing

material can be separated from the fibrinogen layer and/or the thrombin layer after application of the bandage to wounded tissue. In another embodiment, the physiologically-acceptable adhesive has a shear strength such that the resorbable material and/or backing material cannot be separated from the fibrinogen layer and/or the thrombin layer after application of the bandage to wounded
5 tissue.

Suitable fibrinogen and thrombin may be obtained from human or mammalian plasma by any of the purification methods known and available to those skilled in the art; from supernatants or pastes of recombinant tissue culture, viruses, yeast, bacteria, or the like that contain a gene that expresses a human or mammalian plasma protein which has been introduced according to
10 standard recombinant DNA techniques; or from the fluids (*e.g.* blood, milk, lymph, urine or the like) of transgenic animals that contain a gene that expresses human fibrinogen and/or human thrombin which has been introduced according to standard transgenic techniques.

As a general proposition, the purity of the fibrinogen and/or the thrombin for use in the inventive hemostatic sandwich bandage will preferably be an appropriate purity known to one of
15 ordinary skill in the relevant art to lead to the optimal efficacy and stability of the protein.

Preferably, the fibrinogen and/or the thrombin has been subjected to multiple chromatographic purification steps, such as affinity chromatography and preferably immunoaffinity chromatography, to remove substances which cause fragmentation, activation and/or degradation of the fibrinogen and/or the thrombin during manufacture, storage and/or use. Illustrative examples of such
20 substances that are preferably removed by purification include protein contaminants, such as inter-alpha trypsin inhibitor and pre-alpha trypsin inhibitor; non-protein contaminants, such as lipids; and mixtures of protein and non-protein contaminants, such as lipoproteins.

The concentration of the fibrinogen and/or the thrombin employed in the inventive hemostatic sandwich bandage is also preferably selected to optimize both the efficacy and stability thereof, as may be determined empirically by one skilled in the relevant art. During use of the inventive hemostatic sandwich bandage, the fibrinogen and the thrombin are preferably

5 activated at the time the bandage is applied to the wounded tissue by the endogenous fluids of the patient escaping from the hemorrhaging wound. Alternatively, in situations where fluid loss from the wounded tissue is insufficient to provide adequate hydration of the protein layers, the fibrinogen and or the thrombin may be activated by a suitable, physiologically-acceptable liquid, optionally containing any necessary co-factors and/or enzymes, prior to or during application of

10 the hemostatic sandwich bandage to the wounded tissue.

In addition, one or more supplements may also be contained in one or more layers of the inventive hemostatic sandwich bandage, such as growth factors, drugs, polyclonal and monoclonal antibodies and other compounds. Illustrative examples of such drugs include, but are not limited to: antibiotics, such as tetracycline and ciprofloxacin, amoxicillin, and

15 metronidazole; anticoagulants, such as activated protein C, heparin, prostacyclin (PGI₂), prostaglandins, leukotrienes, antithrombin III, ADPase, and plasminogen activator; steroids, such as dexamethasone, inhibitors of prostacyclin, prostaglandins, leukotrienes and/or kinins to inhibit inflammation; cardiovascular drugs, such as calcium channel blockers, vasodilators and vasoconstrictors; chemoattractants; local anesthetics such as bupivacaine; and

20 antiproliferative/antitumor drugs such as 5-fluorouracil (5-FU), taxol and/or taxotere; antivirals, such as gancyclovir, zidovudine, amantidine, vidarabine, ribaravin, trifluridine, acyclovir, dideoxyuridine and antibodies to viral components or gene products; cytokines, such as α - or β - or γ -Interferon, α - or β -tumor necrosis factor, and interleukins; colony stimulating

factors; erythropoietin; antifungals, such as diflucan, ketaconazole and nystatin; antiparasitic agents, such as pentamidine; anti-inflammatory agents, such as α -1-anti-trypsin and α -1-antichymotrypsin; anesthetics, such as bupivacaine; analgesics; antiseptics; and hormones. Other illustrative supplements include, but are not limited to: vitamins and other nutritional
5 supplements; glycoproteins; fibronectin; peptides and proteins; carbohydrates (both simple and/or complex); proteoglycans; antiangiogenins; antigens; lipids or liposomes; oligonucleotides (sense and/or antisense DNA and/or RNA); and gene therapy reagents.

The following examples are illustrative only and are not intended to limit the scope of the invention as defined by the appended claims. It will be apparent to those skilled in the art
10 that various modifications and variations can be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

All patents and publications referred to herein are expressly incorporated by reference.

15 V. EXAMPLES

A. EXAMPLE I

Fibrinogen and thrombin vials were removed from refrigerator and allowed to warm to room temperature for 2 hours. To each vial of thrombin 2mL of 40mM CaCl_2 was added, this yielded a final concentration of 500U/mL of thrombin. Dispo molds (Baxter) size 3.0 X 2.4 cm
20 were placed on freezing tray on top of dry ice.

To each of 12 molds, 1.75 mL of H_2O was added and allowed to freeze for 1 hour at -80°C . Once frozen 140 μL of thrombin (70 units) was pipetted on top of the H_2O and allowed to

freeze for an additional 1 hour at -80°C. Fibrinogen was solubilized with water (8mL) to a concentration of 50mg/mL. To the molds 1.1 mL of fibrinogen was added (55mg) and allowed to freeze for an additional 1 hour at -80°C, followed by the addition of 1mL of H₂O. The bandages were allowed to freeze for 1 hour at -80°C. Then 0.25ml of thrombin (125 units) was added and
5 allowed to freeze for one hour. An additional 1.1 mL of fibrinogen (55mg) was pipetted on top and allowed to freeze for 1 hour.

Once all materials were added and frozen, VICRYL was placed on top and pressed into place, by gentle finger pressure. To cover the VICRYL 500 μ L of 30% sucrose was added and allowed to freeze. The bandages were placed at -80°C for 2 hours, then placed into the freeze
10 dryer. Upon completion, vacuum was released and the bandages were removed and examined.

RESULTS: The bandages when removed from the freeze dryer were uniform and consistent, the VICRYL was attached and all layers were intact.

B. EXAMPLE II

The fibrinogen and thrombin vials were removed from the refrigerator and allowed to
15 warm to room temperature for 2 hours. VicrylTM was applied and pressed into Dispo plastic molds (2.4cm x 2.4cm). The molds were incubated at -80°C for 1 hour.

Fibrinogen was solubilized with 21mL of 2% sucrose or water to a concentration of 19.2mg/mL. In addition, fibrinogen was solubilized to a concentration of 1mg/mL with either 2% sucrose or water. The molds received 1.23mL of fibrinogen and then were frozen at -80°C for 1
20 hour.

Thrombin was solubilized with 0.5mL of 40mM CaCl_2 to a concentration of 2000U/mL. The bandages were removed from the freezer and placed on dry ice. Thrombin was sprayed at 37.5U/cm². The bandages were returned to -80°C for an additional 1 hour.

The bandages were placed on dry ice and received a second layer of fibrinogen (identical
5 to the first layer). Half of the bandages were returned to -80°C for 2 hours and the other half of the bandages were placed at -20°C for 2 hours. Then, the bandages were placed in the freeze-dryer.

The bandages were subjectively assessed for resorbable material adherence and bandage appearance. Table 3 summarizes the experimental design.

Table 3. Various bandage configurations and formulations

Bottom Layer	Second Layer	Third Layer	Fourth Layer	Freeze temp prior to placement into freeze-dryer	Bandage group
Fibrinogen 1mg/cm ² in 2% sucrose	VICRYL™	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	1
Fibrinogen 1mg/cm ² in water	VICRYL™	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	2
Fibrinogen 8mg/cm ² in 2% sucrose	VICRYL™	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	3
Fibrinogen 8mg/cm ² in water	VICRYL™	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	4
VICRYL™	Fibrinogen 1mg/cm ² in 2% sucrose	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	5
VICRYL™	Fibrinogen 1mg/cm ² in water	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	6
VICRYL™	Fibrinogen 8mg/cm ² in 2% sucrose	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	7
VICRYL™	Fibrinogen 8mg/cm ² in water	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	-20°C or -80°C	8

RESULTS: The results from table 3 showed that the best bandage was . This was true for bandages frozen at both -20°C or -80°C.

C. EXAMPLE III

This bandage configuration had Vicryl™ and thrombin "layered" in between two layers of fibrinogen. The first layer of fibrinogen was solubilized in either 2% sucrose or water. The bandages were frozen at -20°C or -80°C prior to placement into the freeze-dryer. The experimental design is

outlined in Table 4. The bandages were subjectively observed for physical appearance after freeze-drying and handling characteristics after hydration.

Table 4. "Layered" bandage configuration

Bottom Layer	Second Layer	Third Layer	Fourth Layer	Fifth Layer	Freeze temp prior to placement into freeze-dryer	Group
2% Sucrose	Fibrinogen 1mg/cm ² in 2% sucrose	VICRYL TM	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	- 20°C or - 80°C	1
2% Sucrose	Fibrinogen 1mg/cm ² in water	VICRYL TM	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	- 20°C or - 80°C	2
2% Sucrose	Fibrinogen 8mg/cm ² in 2% sucrose	VICRYL TM	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	- 20°C or - 80°C	3
2% Sucrose	Fibrinogen 8mg/cm ² in water	VICRYL TM	Thrombin in 40mM CaCl ₂	Fibrinogen 8mg/cm ² in 2% sucrose	- 20°C or - 80°C	4

RESULTS: Two structures for layered bandage production; group 7 at -20°C and -80°C from table 3 and group 1 at -20°C and -80°C from table 4, were exhibited the best characteristics in terms of no separation of layers and attachment of resorbable material.

D. EXAMPLE IV

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to room 25°C for 2 hours. For groups 1 + 2 each vial of fibrinogen received 15.3mL of 2% sucrose, final concentration of 26.2mg/mL; bandages for group 3 had 21mL of 2% sucrose to give a final concentration of 19.2mg/mL. The final amount of fibrinogen was 8mg/cm² for all three groups.

Dispo molds (3.0 X 2.4 cm) were placed on a freezing tray on top of dry ice. 1mL of 2% sucrose was added and allowed to freeze at -80°C for 1 hour, once frozen VICRYL was placed on

top and pressed into place. Groups 1 + 2 received 2.2mL of fibrinogen, whereas group 3 received 1.5mL of fibrinogen..

All bandages were allowed to freeze at -80°C for 2 hours. Group 1 was kept at -80°C until placed into the freeze dryer. Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. Groups 2 & 3 were sprayed with thrombin, so that each bandage received 144U/bandage while on dry ice. Once thrombin was applied the bandages were placed at -80°C for 1 hour. Group 3 was removed from the freezer and placed on dry ice, and an additional 1.5mL of fibrinogen at 19.2mg/mL was added.

When finished all bandages were returned to -80°C for another 2 hours. The bandages were then place into the freeze dryer, after 96 hours a sample of each group of bandages were removed and moisture content determined. Secondary drying was initiated for 24 hours. When the bandages were removed, moisture content was measured again.

RESULTS: As can be seen in table 5 the moisture content of the bandages decreases with secondary drying. All bandages looked identical and had the same texture.

15 Table 5

Bandage Group	% Moisture	
	Pre-Secondary Drying	Post-Secondary Drying
Fibrinogen alone (1)	4.2	3.8
Fibrinogen/Thrombin (2)	4.6	3.3
Fibrinogen/Thrombin/Fibrinogen (3)	4.3	3.9

20 E. EXAMPLE V

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to room 25°C for 2 hours. Dispo molds of size 3.0 X 2.4 cm were sprayed with 300μL of 2% sucrose on dry

ice, VICRYL was applied and pressed into place and the molds placed at -80°C for 1 hour. Fibrinogen was solubilized with 11mL of 2% sucrose, to a concentration of 36.4mg/mL. Each bandage had a final fibrinogen amount of 15mg/cm².

The molds received 1.5mL of fibrinogen and then were frozen at -80°C for 1 hour. Thrombin
5 was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. All bandages were sprayed with thrombin, while on dry ice and received 37.5U/cm².

The bandages were returned to -80°C for an additional 1 hour. The bandages were placed on dry ice and received a second layer of fibrinogen, identical to the first layer. The bandages were again returned to -80°C for 2 hours, until placed into the freeze dryer.

10 RESULTS: The bandages were removed from the freeze dryer and a sample of the 3.0 X 2.4 cm bandages were analyzed for moisture content. These bandages had a moisture content of 2.49%. The bandages were complete and had no separation of layers, and the VICRYL was well attached.

F. EXAMPLE VI

Forty-four square petri dishes with a size of 10.1 X 10.1 cm, with a surface area of 103cm²
15 were placed on shelf trays and received 20mL of 2% sucrose, which is equal to 194 μL /cm². Once the molds were filled they were placed at -80°C for 2 hours until frozen, and then VICRYL applied.

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Each vial of fibrinogen was solubilized with 10mL of 2% sucrose. The concentration of fibrinogen when reconstituted was 16mg/mL. The molds received 25mL of fibrinogen and where
20 returned to -80°C for 2 hours until frozen. Thrombin was solubilized with 0.5mL of 40mM CaCl₂

to a concentration of 2000U/mL, and sprayed on top of the fibrinogen and returned to -80°C for 1 hour. An additional 25mL of fibrinogen was added and allowed to freeze at -80°C for 2 hours.

The bandages were then freeze dried, upon completion the bandages were packaged and sent for *in vivo* testing, described *supra*.

5 G. EXAMPLE VII

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (3.0cm x 2.4cm) were placed on dry ice and sprayed with 300μL of 2% sucrose. Vicryl™ or calcium alginate was applied and pressed into place. The molds were incubated at -80°C for 1 hour.

10 The calcium alginate was used in two ways. In the first method, the calcium alginate was cut to the same size section as the Vicryl™ sections. In the second method, the calcium alginate was also cut to the same size section as the Vicryl™ sections, but then it was shredded into fine pieces of material (Table 6).

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4mg/mL. Each
15 bandage had a final fibrinogen amount of 15mg/cm². The molds received 1.55mL of fibrinogen and then were frozen at -80°C for 1 hour. Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. The bandages were placed on dry ice and sprayed with thrombin to yield 37.5U/cm².

The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer.
20 After the bandages were freeze-dried, they were tested in the porcine arteriotomy bandage performance test.

Table 6. Bandage resorbable material combinations using VicrylTM and Calcium alginate

Bandage	Vicryl	Calcium Alginate
1	No	Whole
2	No	Shredded
3	Yes	Shredded
4	Yes	Whole

Porcine Arteriotomy Bandage Performance Test

Obtain frozen porcine aorta and thaw. Aortas can be thawed overnight at 4°C, or individually wrapped in the water bath at 37°C. Dissect excess connective tissue from approximately first 11 cm of the aorta. Usually, the first 5-5.5 cm are free from collateral vessels. The next 5-5.5 cm should not have more than 1-2 collaterals. These can be easily sealed or patched with cyanoacrylate glue.

Cut the aorta into two 5.5 cm pieces. Invert aorta exposing the interior using a hemostat or blunt forceps. Wash both the interior and exterior of the vessel with 1-5 mL of PBS at 37°C. Stretch an O-ring over a 20cc syringe with an approximately 0.6 cm (0.25 in) hole drilled into one side. Using fingers or hemostats pull the vessel onto the syringe. Fit another O-ring of the same size onto the bottom.

Using curved hemostats, carefully secure both O-rings over the top of the vessel. The distance between both O-rings should be 3.5 cm. The artery should be snug fitting and held securely in place. Position the secured vessel such that the hole in the syringe lies in the middle of the distance between the O-rings.

Fill the syringe with PBS at 37°C and place the screw through the outside of the syringe and into the plunger, so that the plunger is held in a stationary position. Wash the artery on the syringe with 1-2ml of PBS at 37°C. Using a 16-gauge needle, make a hole in the center (approximately 1.75

cm from either O-ring) over the syringe hole. The 16-gauge needle should be replaced after every 12 uses.

Open the sealed bag containing the bandage and immediately place the bandage over the incision (approximately 0.5 cm from each O-ring, so as not to touch either O-ring). All bandages
5 should be individually packaged prior to use.

Using a P-1000 Pipetman, wet the bandage with PBS at 37°C. For 15 mg/cm² bandages use 800 µL, and for 8 mg/cm² bandages use 500 µL. Immediately place the syringe shield on top of the bandage, so as not to touch either O-ring. Press lightly to secure.

Place the syringe into the incubator at 37°C using the holding box in order to keep the syringe
10 and all its components stationary. Cover with the plastic cover, placing a 200g weight securely over top. Assure even distribution of weight. Allow it to incubate for 5 minutes at 37°C.

Remove the syringe from the incubator. Carefully remove the shield covering the bandage. Attach the syringe to the tubing connected to a peristaltic pump. The tubing should be arranged so that it runs through the pump and is connected to a Y-junction on the opposite side. The Y-junction
15 creates two outlets, allowing the PBS to be pumped into the syringe at one site as back pressure is being generated in the other. This back pressure is directly measured using an in-line pressure transducer-analyzer, and recorded using DMSI-200/1 software.

Pump the PBS at 37°C into the syringe, and immediately start monitoring the pressure generated. Initiate a 30-second slow ramp (setting 4 at 1x speed for pump in E229, setting 7.5 at 1x
20 speed for pump in E132), such that the initial flow rate is approximately 0.3 mL/min.

After the first 30 seconds, the flow rate is escalated to approximately 3 mL/min (10x speed, both settings). This should be done until a pressure of 200 mm Hg is obtained. Once 200 mm Hg is achieved, start the timer for 2 minutes.

Stop the pump once 200 mmHg is obtained. Monitor the pressure generated. If pressure starts to drop, turn pump back on until adequate pressure is obtained. This may be done as often as necessary throughout the two-minute interval (under normal conditions, the pressure should be maintained between 200 and 215 mm Hg.). In addition, note any leakage and its location. If a leak
5 occurs, note the maximum time and burst pressure at the moment of leakage. Judge bandage performance based on the following pass / fail criteria.

A bandage is considered passing if it maintains a fairly consistent pressure of 200 mm Hg for two minutes with absolutely no leakage. A bandage is also considered passing if it maintains a fairly consistent pressure of 200 mm Hg for two minutes with only minimal leakage (e.g., slow seeping or
10 a leak that has resealed itself).

A bandage is considered failing if it cannot maintain adequate pressure due to severe leakage. This includes leakage caused by poor adhesion, as well as leakage due to manufacturing flaws.

RESULTS: The results of the experiment showed that bandages can be prepared using calcium
15 alginate as a resorbable material or used as an additional component to the fibrinogen. There was no difference in the appearance of the bandages when removed from the freeze dryer. In addition, all groups of bandages when tested in the porcine arteriotomy assay held 200mm Hg for 3 minutes.

H. EXAMPLE VIII

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for
20 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with 300µl of 2% sucrose. Some of the molds had VicrylTM applied and pressed into place and other molds had Gelfoam® applied and pressed into place as a resorbable material.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4mg/mL for the 15mg/cm² bandages. Collagen Type I was solubilized with 95% ethanol to a concentration of 36.4mg/mL.

In addition to the 15mg/cm² bandages, 8mg/cm² bandages were also prepared. The molds received 1.23mL of fibrinogen or collagen and then were frozen at -80°C for 1 hour. Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. The bandages were placed on dry ice and sprayed with thrombin.

The bandages were returned to -80°C for an additional hour. Then the bandages were placed on dry ice and received a second layer of fibrinogen (identical to the first layer). The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer.

Table 7 summarizes the experimental design. After freeze-drying, the bandages were subjectively assessed for their physical appearance.

Table 7. Formulation and configuration of bandages using different resorbable materials and different protein components

1st Layer	2nd Layer	3rd Layer	4th Layer	5th Layer
2% sucrose	Vicryl	Collagen I 15mg/cm ²	Thrombin	NA
2% sucrose	Vicryl	Collagen I 8mg/cm ²	Thrombin	NA
2% sucrose	NA	Collagen I 15mg/cm ²	Thrombin	NA
2% sucrose	NA	Collagen I 8mg/cm ²	Thrombin	NA
2% sucrose	Vicryl	Fibrinogen 15mg/cm ²	Thrombin	Fibrinogen 15mg/cm ²
2% sucrose	Vicryl	Fibrinogen 8mg/cm ²	Thrombin	Fibrinogen 8mg/cm ²
2% sucrose	Vicryl	Fibrinogen 7.5mg/cm ² + Collagen 7.5mg/cm ²	Thrombin	Fibrinogen 7.5mg/cm ² + Collagen 7.5mg/cm ²
2% sucrose	Vicryl	Fibrinogen 4mg/cm ² + Collagen 4mg/cm ²	Thrombin	Fibrinogen 4mg/cm ² + Collagen 4mg/cm ²
2% sucrose	Gelfoam	Thrombin	NA	NA
2% sucrose	Gelfoam	Fibrinogen 15mg/cm ²		Fibrinogen 15mg/cm ²
2% sucrose	Gelfoam	Fibrinogen 8mg/cm ²		Fibrinogen 8mg/cm ²

RESULTS: After freeze drying the bandages were evaluated for their physical appearance. All combinations manufactured produced satisfactory bandages. In that they were all intact and had no separation of layers.

I. EXAMPLE IX

5 Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (3.0cm x 2.4cm) were placed on dry ice and sprayed with 300 μ L of 2% sucrose. VicrylTM was applied and pressed into place. The molds were incubated at -80°C for 1 hour.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4mg/mL. Each
10 bandage had a final fibrinogen amount of 15mg/cm². Each group of bandages received their pre-determined designated amount of fibrinogen (as listed in Table 8). The bandages were then frozen at -80°C for 1 hour.

Table 8. Bandage configurations with various percentages of fibrinogen

15	1st Layer: % Fibrinogen	Volume (ml) Fibrinogen	% Thrombin	2nd Layer: % Fibrinogen	Volume (ml) Fibrinogen
	100	3.1	100	0	0
	0	0	100	100	3.1
	75	2.325	100	25	0.775
	25	0.775	100	75	2.325
20	50	1.55	100	50	1.55

Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. The bandages were placed on dry ice and sprayed with thrombin at 37.5U/cm².

The bandages were returned to -80°C for an additional hour. The bandages were placed on dry ice and received a second layer of fibrinogen (as listed in Table 8). The bandages were returned
25 to -80°C for 2 hours until they were placed into the freeze-dryer.

After freeze-drying, the bandages were tested in the porcine arteriotomy test. Bandages were tested on day 0 and two months post manufacturing after room temperature storage in foil bags.

Table 9. Porcine arteriotomy test results with various percentages of fibrinogen bandages

5	% Fibrinogen (Bottom Layer)	% Thrombin (Middle Layer)	% Fibrinogen (Top Layer)	% Bandages that Passed Porcine Arteriotomy Test:	
				Time 0	Time 2 months
	100	100	0	0	0
	0	100	100	16.6	33.375
	75	100	25	50	66.67
	25	100	75	50	66.67
10	50	100	50	100	100

RESULTS: These results clearly show that the bandage produced with fibrinogen at 50% for the first layer and 50% for the second layer (fibrinogen 50/50 bandages) performs far superior to all other tested combinations of the bandages in this porcine arteriotomy model. Both at time 0 and 2 months, 100% of the fibrinogen 50/50 bandages passed the porcine arteriotomy test.

J. EXAMPLE X

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with 300 μ L of 2% sucrose. VicrylTM was applied and pressed into place and the molds were placed at -80°C for 1 hour.

Fibrinogen was solubilized with 1 mL of 2% sucrose to a concentration of 36.4mg/mL. Each bandage had a final fibrinogen amount of 15mg/cm². The molds received 1.23mL of fibrinogen and then were frozen at -80°C for 1 hour.

Thrombin was solubilized with 40mM CaCl₂, 13mM CaCl₂, or 4mM CaCl₂. The bandages were placed on dry ice and sprayed with thrombin at either 37.5U/cm², 12.5U/cm², 4.2U/cm², or 1.4U/cm². The bandages were returned to -80°C for an additional hour.

The bandages were placed on dry ice and received a second layer of fibrinogen (identical to the first layer). The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer. After the bandages were freeze-dried, they were evaluated for physical appearance and tested in the porcine arteriotomy test.

RESULTS: In this experiment, the bandages were produced using 40mM, 13mM, or 4mM CaCl₂ to solubilize the thrombin and the bandages received thrombin at 37.5U/cm², 12.5U/cm², 4.2U/cm², or 1.4U/cm². Table 10 shows the experimental design and the results.

Table 10. Bandage (with variations in thrombin amount and CaCl₂ concentration) performance in the pig arteriotomy test

Thrombin Units/cm ²	CaCl ₂ mM	Results	
		% Bandages Separated Following Freeze Drying	% Bandages Pass Pig Arteriotomy
1.4	4.4	100	0
4.2	4.4	100	0
12.5	4.4	100	0
37.5	4.4	0	0
1.4	13	87.5	50
4.2	13	25	0
12.5	13	12.5	75
37.5	13	0	100
1.4	40	87.5	0
4.2	40	12.5	83
12.5	40	12.5	100
37.5	40	0	100

The results from Table 10 show that the best combination for the bandage is 37.5U/cm² of thrombin solubilized in either 13mM or 40mM CaCl₂. This combination is superior to all other combinations tested in both physical appearance and ability to pass the porcine arteriotomy test. These two combinations of the bandage exhibited no separation of the component layers after freeze-drying and 100% of the bandages passed the porcine arteriotomy test.

It should be noted that there were no adjustments made in the freeze-drying cycle when these bandages were manufactured so it is possible the cycle could be modified in such a way to consistently prepare bandages with lower thrombin and/or CaCl₂ amounts. However, a decrease in the amount of thrombin would prolong the amount of time needed for fibrin formation and may jeopardize the quality of the bandage, especially in case of trauma where the temperature of the body may be lower than normal thereby decreasing the bodies own clotting ability.

K. EXAMPLE XI

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with 300μl of 2% sucrose. VicrylTM was applied and pressed into place. The molds were placed at -80°C for 1 hour.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4mg/mL for 15mg/cm², 21mL of 2% sucrose to a concentration of 18.7mg/mL for 8mg/cm², 42.8mL of 2% sucrose to a concentration of 9.35mg/mL for 4mg/cm², and 85.6mL of 2% sucrose to a concentration of 4.68mg/mL for 2mg/cm². The molds received 1.23mL of fibrinogen and then were frozen at -80°C for 1 hour.

Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. The bandages were placed on dry ice and sprayed with thrombin.

The bandages were returned to -80°C for an additional hour. The bandages were placed on dry ice and received a second layer of fibrinogen (identical to the first layer).

The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer. After the bandages were freeze-dried, they were observed for their physical appearance and tested
5 in the porcine arteriotomy test.

Table 11. % Bandages That Maintained 200mm Hg for 3 minutes in Porcine Arteriotomy Assay

10	Fibrinogen Concentration mg/cm ²	% Bandages to Maintain 200mm Hg
	15	100
	8	50
	4	37.5
	2	18.75

15 L. EXAMPLE XII

Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with $300\mu\text{L}$ of 2% sucrose.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4 mg/mL.
20 Each bandage had a final fibrinogen amount of $15\text{mg}/\text{cm}^2$. The molds received 1.23mL of fibrinogen and then were frozen at -80°C for 1 hour.

Thrombin was solubilized with 40mM CaCl_2 , the bandages were placed on dry ice and sprayed with thrombin at $37.5\text{U}/\text{cm}^2$. The bandages were returned to -80°C for an additional hour.

25 The bandages were placed on dry ice and received a second layer of fibrinogen (identical to the first layer). VICRYLTM was applied and pressed into place and the molds were sprayed

with 300 μ L of 2% sucrose. The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer.

RESULTS: The bandages were evaluated for physical appearance when removed from the freeze dryer. Although the bandages layers were intact the VICRYL was not attached to the bandage.

5 M. EXAMPLE XIII

Fibrinogen was removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with 300 μ L of 2% sucrose. Calcium alginate was applied and pressed into place.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4 mg/mL.

- 10 Each bandage had a final fibrinogen amount of 15mg/cm². The molds received 2.4 mL of fibrinogen and then were frozen at -80°C for 2 hours, then placed into the freeze dryer.

RESULTS: The bandages when removed from the freeze dryer were intact.

N. EXAMPLE XIV

- 15 Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (2.4cm x 2.4cm) were placed on dry ice and sprayed with 300 μ L of 2% sucrose. VicrylTM was applied and pressed into place. Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4 mg/mL; in addition each vial received 0.2 grams of CHAPS. Each bandage had a final fibrinogen amount of 15mg/cm². The molds received 1.23mL of fibrinogen/CHAPS and then were frozen at -80°C for 1 hour.

Thrombin was solubilized with 40mM CaCl₂; the bandages were placed on dry ice and sprayed with thrombin at 37.5U/cm². The bandages were returned to -80°C for an additional hour.

The bandages were placed on dry ice and received a second layer of fibrinogen/ CHAPS
5 (identical to the first layer). The bandages were returned to -80°C for 2 hours until they were placed into the freeze-dryer.

RESULTS: The bandages when removed from the freeze dryer were intact and uniform in shape.

O. EXAMPLE XV

The mean burst pressure of bandages incorporating different backing material and a
10 fibrinogen concentration of 15 mg/cm² was determined.

	BACKING MATERIAL	FIBRINOGEN CONCENTRATION	MEAN BURST PRESSURE (mm Hg)	ADHERENCE TO BACKING MATERIAL
	DEXON #2 2000 micron	8mg/cm ²	15	NO
15	DEXON #4 230 micron	8mg/cm ²	250*	YES
	DEXON #8 100 micron	8mg/cm ²	181	NO
20	VKML KNITTED MESH	8mg/cm ²	250*	YES
	VWML WOVEN MESH	8mg/cm ²	210	NO

* All of the bandages maintained mean burst pressure for the maximum test period of 3 minutes.

RESULTS: Maximum mean burst pressure and time was achieved with bandages at a
25 concentration of 8 mg/cm². The mean burst pressure for VICRYL and Dexon meshes alone is zero.

P. EXAMPLE XVI: SUMMARY OF IN VIVO DATA

Layered (fibrinogen 50/50) bandage application methods

Layered fibrinogen/thrombin/fibrinogen bandages at 15 mg/cm² fibrinogen were tested in the rat arterial hemorrhage model using two distinct application methods for the bandage: 1) the 5 500 g weight on a molded platform was used to apply pressure for fifteen minutes and with the variation that an additional one minute of pressure was applied if bleeding was noted or 2) finger pressure was applied for 7 minutes, and in the latter part of the study with the option to apply a second bandage with finger pressure for an additional 3 minutes if bleeding was noted after the first bandage. In all cases by either method, the bandage was applied to a dry field and the blood 10 flow from the artery was used to soak the bandage.

Rat Hemorrhage Model

Animals: Model: Rat; Vendor: Harlan Sprague Dawley; Strain: Sprague Dawley; Color: White; Age: 120 days to 180 days; Sex: Male; Weight: 400g to 500g.

Anesthesia:

- 15 1) 1.1 g/Kg of 55% w/v Urethane (methyl carbamate) given IP
- a) Urethane supplied by: Sigma (lot 55H0368)
 - b) Urethane prepared fresh daily by weighing out 2.0g urethane into a sterile glass rubber-top tube (Becton Dickson, Vacutainer, 5 ml Draw Lot # 6A715 exp. Dec 97). An equal weight / volume (2.0 cc) sterile water for injection (Abbot Laboratories, 10ml Sterile Water for Injection, 20 U.S.P., Lot 11-221-DK, Exp Dec 1, 97) is added to produce a final solution volume of 3.6 mL (producing a solution of 55.56% urethane). This preparation procedure is performed in a biological safety cabinet (Forma Scientific, model 1168, serial no. 14088-43).

c) The urethane injection is drawn into, and administered with, a 1cc syringe (Becton Dickinson, tuberculin 1cc syringe, sterile Lot no. 3E345) with a 23 gauge, 3/4 inch needle (Becton Dickinson, PrecisionGlide needle, sterile Lot no. 4B047). The rat is weighed, manually restrained, and the urethane is injected intraperitoneally (IP) into the left caudal quadrant of the ventral abdomen. The volume injected ranges from 0.80 to 1.00 mL for rats weighing 400 to 500 g to deliver a dose of 1.1 g/Kg.

d) Time clock started immediately after urethane injection recorded as T=0

2) 0.06 mg/Kg atropine and 0.15 mg/Kg buprenorphine given together IM.

a) Atropine sulfate supplied by: Phoenix Pharmaceutical, Inc. (Lot# 5110547, Exp. 11/96)

10 b) Buprenorphine HCl (Buprenex) supplied by: Reckitt & Colman Pharmaceuticals
(CN#3555, Exp. 1, Feb. '99)

c) Atropine is drawn first into a 1cc syringe (ibid) with a 26 gauge, 1/2 inch needle (Becton Dickinson, PrecisionGlide needle, sterile Lot no. 4B046), then the buprenorphine is drawn into the same syringe. The rat is given an intramuscular injection in the caudal thigh with the same syringe and needle when it has lost its righting reflex (2 - 3 minutes after the urethane injection). The volume injected is 0.04 to 0.05 mL of atropine, and 0.20 to 0.25 mL of buprenorphine, making a total volume of 0.24 to 0.30 mL for 400 - 500g rats.

d) Time of injection recorded to nearest minute

Surgery:

20 1) Shave animal:

a) Right axillary region for placement of thermoprobe

b) Ventral Neck for right carotid artery cannulation

c) Ventral abdominal midline for laparotomy

2) Thermoprobe placement:

- a) Stab incision right axilla with #15 or #17 scalpel blade
- b) Subcutaneous tissue undermined caudal to incision with Hartman mosquito forceps.
- c) Thermoprobe (Traceable™, Certification of Calibration for Digital Thermometer, Model

5 Number 15-078-39, Serial Number 566680) placed subcutaneously and temperature recorded

- d) Time of thermoprobe placement recorded to nearest minute
- e) Body temperature is maintained between 33 and 39 C by use of electric heat support

3) Carotid arterial cannulation/pressure transducer placement (under operating microscope):

- a) Ventral neck incised with from manubrium to mandibular symphysis -- time recorded
- 10 b) Cervical musculature bluntly dissected along fascial planes, exposing right carotid artery
- c) Carotid artery bluntly dissected from surrounding tissue and distracted ventrally
- d) Distal end of carotid exposure ligated with 4-0 silk, proximal end elevated with a length of 4-0 silk, and a third length of 4-0 silk placed under the artery midway between.
- e) Beveled arteriotomy made with microvascular scissors and the transducer/catheter

15 (Millar Mikro-Tip Catheter Pressure Transducer System, Size 2F, Model SPR-407) inserted into the artery 2-3 cm proximally, then ligated using the third length of silk with a quick release knot.

f) Instruments and elevating suture removed from the field, neck incision partially closed with a staple, and the rat situated in preparation for the laparotomy

g) Computerized data collection is begun -- time recorded.*

20 h) At least five sets of data recorded at one minute intervals (mean arterial pressure, systolic and diastolic pressures, and heart rate readings), averaged over each minute.

4) Laparotomy (under operating microscope):

- a) Ventral midline incision from xiphoid to pubis through skin and linea alba.

b) Abdominal incision retracted with Weitlaner Retractor (3x4 8"sharp) , small intestine exteriorized to right side of animal and covered with warm saline moistened gauze, colonic mesentery bluntly dissected and colon displaced to the right.

c) Retroperitoneum bluntly dissected, exposing lumbar region of aorta/vena cava distal to
5 the renal arteries. Adipose tissue cleaned away from vessel complex and surrounding muscle bed, creating a window approximately 2 - 3 cm diameter.

d) Diameter of aorta measured with micrometer calipers and documented.

e) Aorta clamped with Jacobson micro mosquito hemostatic forceps at cranial edge of window just distal to the renal arteries and clamped with Dieffenbach Micro Clamp at the caudal
10 edge of window.

f) A 4 mm longitudinal incision is made using a microvascular scalpel and arteriotomy scissors on the ventral aspect of the aorta at the level of, or just distal to, the large lumbar veins. Incision measured with micrometer calipers and an ocular rule installed in the microscope eyepiece is utilized to guide the incision-making process.

15 g) Distal aortic clamp removed, proximal aortic clamp briefly released allowing approx. 0.5 - 1.0 ml of blood to fill the window, and to clear the artery of potential thromboses.

h) Bandage (either experimental fibrin sealant powder or IgG powder placebo control) placed onto the arteriotomy site, a custom made cylindrical molded platform (made with Bondo TM epoxy compound molded in a cylinder with one end against the internal side of a 400g rat's
20 back and gently sanded to a general conformation, weight = 15.2g) covered in thin plastic wrap placed over bandage, then a 500g cylindrical brass weight (OHAUS) placed on platform and stabilized from tilting with a ring stand. This step done as quickly as possible (<1 min) and gentle manual pressure is applied throughout these manipulations.

i) Proximal aortic clamp is removed. If bleeding noted, a few seconds of manual pressure is applied and minor adjustments to position/angle of weight are made to achieve hemostasis. Often the weight tilts slightly forward less than 5 degrees. If hemostasis can not be achieved or excessive hemorrhage occurs (as indicated by MAP just prior to lifting the weight -- see exclusion
5 criteria below), then the animal must be excluded.

j) After 10 minutes of pressure, the weight is lifted and visible hemorrhage noted. If the MAP is <60 mmHg during the one minute period prior to lifting the weight (indicating excessive hemorrhage has occurred prior to this point, or that the animal is responding aberrantly to the anesthesia), then the animal must be excluded. After one more minute, the molded platform is
10 carefully removed, exposing the undisturbed bandage.

k) The animal is monitored until death occurs from exsanguination, or if hemostasis maintained, up to a maximum of 30 minutes. A positive result is hemostasis with the animal surviving the entire 30 minutes. A negative result is hemorrhage with death by exsanguination within the 30 min. test period. An intermediate result is survival through the 30 min. test period
15 but the MAP not maintained above 50 mmHg.

l) If the rat survives the 30 min. test period, the carotid transducer is removed and exsanguination allowed to occur. After death, the blood is swabbed from the peritoneal cavity with reweighed gauze pads and the gauze reweighed to estimate blood loss. The bandage and arteriotomy site are inspected and the arterial incision is remeasured to confirm a length of 4 mm
20 +/- 0.5 mm.

Summary of inclusionary/exclusionary criteria and experimental endpoints:

1) Inclusion criteria for rat selection:

a) HSD albino males

b) Weight between 400 and 500 g.

c) Age between 120 and 180 days

2) Inclusion criteria for procedural parameters:

a) MAP at least 80 mmHg average during the 5 minute period prior to laparotomy

5 b) HR between 300 and 500 bpm during the 5 minute period prior to laparotomy

c) MAP at least 60 mmHg average during the 1 minute period prior to lifting the weight

d) Length of aortic incision between 3.5 and 4.5 mm confirmed at end of procedure

3) Exclusion criteria for procedural parameters

a) Uncontrolled hemorrhage from a site other than the aortic arteriotomy

10 b) Death for some reason other than obvious hemorrhage

c) Uncorrectable surgical or procedural error

d) Any animals that do not meet the inclusion criteria above

4) Experimental endpoints

a) Primary endpoints

15 -Hemostasis

-Survival for 30 minutes after release of pressure on bandage

b) Secondary endpoints

-MAP maintained above 50mmHg for the entire 30 minutes of survival

c) Strong positive result

20 -meets both primary and secondary endpoints

d) Intermediate positive result

-Meets primary but not secondary endpoints

e) Negative result

-Hemorrhage leading to death within 30 min.

RESULTS: This study showed that with the layered bandage applied by two different techniques yielded a success rate of exactly 50% by either method with an N of ten animals included per group.

With the weight and platform method, ten of nineteen animals were included in the study (5 pre-treatment and 4 post-treatment exclusions) with two post-treatment exclusions not surviving despite apparent hemostasis. Five of the ten included animals survived the 30 minute test period, while three of these survivors exhibited complete hemostasis.

With the application of a single bandage using finger pressure, ten of twelve animals were included (1 pre-treatment, and 1 post-treatment exclusion which died despite apparent hemostasis) with five of the ten subjects surviving thirty minutes. A second bandage was applied in an additional six animals, four of which were included (both pre-treatment exclusions), and two of the four included animals survived thirty minutes. Often, there was not enough time to apply a second bandage before too much blood had been lost. In nearly all cases of failure, the blood flow from the artery dissected the plane between the bandage and the tissue -- in only one case was blood seen flowing through the bandage matrix. The adherence of the bandage to the tissues was good except where natural hematomas had formed under the bandage creating a pocket of weaker fibrin. In many cases, the bandage was not fully saturated by the blood.

Arterial hemorrhage model in the rabbit

The rabbit aorta model has several advantages over the rat model: the artery can be isolated from the underlying tissue to provide direct access to the injury site, a plate can be placed under the aorta to provide a background for applying pressure, the artery is large enough to test various incision sizes and configurations, and the rabbit has a large enough blood volume to tolerate reasonable blood losses necessary to soak the bandage or apply multiple bandages. A

disadvantage of the rabbit is lack of a good anesthetic regimen that can maintain high blood pressures -- a problem that was addressed by the use of vasopressors.

New Zealand white male rabbits weighing 2.9-3.3 kg have been used in this study. Rabbits are premedicated with buprenorphine and glycopyrrholate, and anesthesia induced with ketamine and xylazine, administered IM. An endotracheal tube is placed via tracheotomy and mechanical ventilation assistance is provided. Anesthesia is maintained by isoflurane in oxygen. The animals' condition is monitored by electrocardiography and visual observation. A 22 gauge angiocath is inserted in the left medial ear vein and IV drip of Lactated Ringer's solution is administered at a surgical rate of 20 ml/Kg/hr. Bilateral vagotomy is performed in order to avoid vagally-mediated cardiovascular effects. A solid state pressure transducer is inserted in the right common carotid artery to monitor blood pressures and computer recording is initiated.

The abdominal aorta is exposed via a ventral midline laparotomy, and the aorta is carefully dissected away from the vena cava and surrounding tissues. Small branching arteries are ligated or cauterized, isolating a 6 - 8 cm length of artery. A plastic rectangular plate is inserted under exposed portion of the aorta. Blood flow is occluded distally and proximally with Jacobsen hemostatic forceps. A 5 mm longitudinal incision is made with a microblade and fine scissors.

A 15 mg/cm² (2.4 x 2.4 cm.) fibrinogen/thrombin/fibrinogen bandage applied to an injured site by a variety of techniques being tested in the initial studies. A soft gel-filled plastic pad is applied over the bandage and 500 gram weight is placed on the top of the pad. The clamps are removed and the weight is used to apply pressure for ten minutes (this time period will vary in subsequent studies). After the specified time, the weight and gel-pad are removed. Shortly afterward the plastic plate is carefully removed from under the bandage. The observation period is thirty minutes after removal of the weight. Five minutes into the observation period, a phenylephrine IV drip is initiated to boost the animal's mean arterial pressure above 100 mmHg

and is continued at increasing rates until the end of the observation period or death of the animal from exsanguination.

The preliminary model development study involves at least the following five groups: 1) dry bandage placed under the aorta, soaked with 2 - 3 mL of saline, and folded around the injury
5 site before the weight is applied; 2) as in group 1, but the bandage is soaked with blood freshly drawn from the animal; 3) dry bandage placed flat over the incision and soaked with saline just before pressure is applied; 4) dry bandage placed flat over the incision and allowed to soak with blood flowing from the artery; and 5) a placebo bandage applied by the most effective technique above. In the fourth group, the clamps are released immediately after the bandage is in place to
10 allow blood flow, and the weight is applied as soon as blood flow is visibly soaking the bandage.

RESULTS: Hemostasis occurs in 50% of animals when the bandage is hydrated by blood flowing from the wound itself, but hemostasis is achieved in 100% of animals under controlled conditions where saline was used to wet the bandage. The reason for the differences seen when blood flowing from the artery was used to soak the bandage are unclear.

15

Prostatectomy hemorrhage model in the dog

Fibrinogen/thrombin/fibrinogen bandages were prepared for a canine prostatectomy study. The fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Dispo plastic molds (3.0cm x 2.4cm and 3.7cm x 2.4cm) were placed on dry ice and
20 sprayed with 300 μ L of 2% sucrose. VicrylTM was applied to the molds and pressed into place. The molds were incubated at -80°C for 1 hour.

Fibrinogen was solubilized with 11mL of 2% sucrose to a concentration of 36.4 mg/mL. Each bandage had a final fibrinogen amount of 15mg/cm². The 3.0 x 2.4cm molds received

1.5mL of fibrinogen; whereas, the 3.7 x 2.4cm molds received 1.75mL of fibrinogen. The bandages were frozen at -80°C for 1 hour.

Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. All of the bandages were placed on dry ice and sprayed with thrombin. Each bandage received
5 thrombin at 37.5U/cm². The bandages were returned to -80°C for an additional 1 hour.

The bandages were placed on dry ice and received a second layer of fibrinogen (identical to the first layer). The bandages were returned to -80°C for 2 hours and then they were placed into the freeze-dryer.

In this prostatectomy model, a midline abdominal incision is made and a splenectomy
10 performed. The prostate is bluntly dissected free and the urethra is isolated just distal to the prostate. The urethra is incised anteriorly, the foley catheter is drawn upward into the wound, and the posterior urethra transected. The vascular pedicles to the prostate are transected sharply. Bleeding is controlled with lap sponges and manual pressure while the bladder neck is dissected free from the prostate. The prostate is delivered from the operative field.

15 At this point, if there is bleeding, vessels are isolated and ligated. The time to achieve hemostasis is measured from the time the prostate is delivered until there is no further bleeding. Acute blood loss is calculated by subtracting the weight of the lap sponges preoperatively from the post operative weight.

The study was comprised of four experimental treatment groups: control, fibrin sealant
20 bandage, placebo bandage, and liquid fibrin sealant. The control is the application of lap sponges and manual pressure. The experimental group is the application of the fibrin sealant bandage over the bleeding area prior to placing the lap sponges and manual pressure. Additionally, the anastomosis is wrapped with two (1 x 3 cm) bandages. The placebo bandage is a visually identical layered lyophilized IgG protein preparation which is treated the same as the experimental

fibrin sealant bandage group. The liquid fibrin sealant is fibrinogen, Factor XIII, and thrombin solutions that are mixed and applied to bleeding surfaces prior to pressure application.

Additionally, 6ml of this sealant is applied to the anastomosis.

RESULTS: The preliminary results from this canine prostatectomy study indicate that the fibrin

5 sealant bandage successfully controls bleeding in this model (Table 12).

Table 12. Efficacy of fibrin sealant bandage in canine prostatectomy study

	Control	Placebo bandage	Fibrin sealant bandage	Liquid fibrin sealant
Number of animals	4	5	3	3
Blood loss (mL)	240 \pm 22	249 \pm 22	114 \pm 9	238 \pm 32
Ligated vessels	4/4	5/5	0/3	3/3

- 10 In the table, "ligated vessels" refers to the number of animals that needed vessels ligated in order to stop bleeding after the prostate is removed. Only the dogs that were treated with the fibrin sealant bandage did not need vessels ligated.

Liver injury hemorrhage model in the pig

Layered bandages were prepared for a swine liver injury model. Fibrinogen and thrombin were removed from the refrigerator and allowed to warm to 25°C for 2 hours. Forty-four square petri dish
15 molds (10.1cm x 10.1cm), with a surface area of 103cm², were placed on shelf trays from the freeze-dryer. Each petri dish received 20mL of 2% sucrose to yield 194μL/cm².

After adding the 2% sucrose, the molds were placed at -80°C for 2 hours until frozen. VicrylTM was applied and pressed into place. The molds were returned to -80°C for 1 hour.

Each vial of fibrinogen was solubilized with 10mL of 2% sucrose to a final concentration of
20 16mg/mL. The molds received 25mL of fibrinogen and were returned to -80°C for 2 hours until frozen.

Thrombin was solubilized with 0.5mL of 40mM CaCl₂ to a concentration of 2000U/mL. The bandages were placed on dry ice, sprayed with thrombin and incubated at -80°C for 1 hour.

An additional 25mL of fibrinogen was added on top of the thrombin. The bandages incubated at -80°C for 2 hours until they were placed into the freeze-dryer.

After freeze-drying, the bandages were packaged and sent testing in the swine liver injury study.

Studies were conducted to test the efficacy of the fibrin sealant bandage and to determine the effect of fibrinogen dose on blood loss. Under general anesthesia, each pig underwent laparotomy and splenectomy. Following a 15 minute period, a Grade IV liver injury was induced using a specially designed instrument. After 30 seconds, the bandages were applied to the injury. Resuscitation with lactated Ringer's solution was simultaneously initiated and the animals were resuscitated to pre-injury mean arterial pressure. The abdominal incision was then closed and the pig was monitored for 60 minutes. The animals were euthanized at 60 minutes. Blood samples were collected at pre-injury and at 30 and 60 minutes post-injury. CBC, fibrinogen, PT, and PTT were determined at each time point. At 60 minutes, the total fluid use and the volume of blood present in the abdominal cavity (total blood loss) were determined. Additionally, the liver was excised and the injury was scored to confirm a Grade IV injury.

RESULTS: The study of a porcine liver injury model to test the efficacy of the fibrin sealant (FS) bandage to prevent hemorrhage has shown that the FS bandage is far superior to standard treatment using fluid resuscitation and gauze application. The study consisted of four groups: (1) no treatment, (2) IgG bandage (placebo), (3) gauze packing, and (4) fibrin sealant bandage. All animals in each group received fluid resuscitation to compensate for the shed blood. The animals were monitored for 60 minutes.

Group 1 (no treatment group) lost $6,025 \pm 1,020$ cc of blood per animal and the animals died. Group 2 (placebo bandage) lost $4,222 \pm 1,554$ cc of blood per animal and the animals died. Group

3 (gauze application group) lost $1,104 \pm 263$ cc of blood per animal. Group 4 (fibrin sealant bandage group) lost 544 ± 104 cc of blood per animal.

Similar results were observed when pigs were made coagulopathic by both dilution and hypothermia, except that under these more stringent conditions, the animals treated with gauze packing exsanguinated, while those treated with the fibrinogen/thrombin/fibrinogen bandage survived.

Initial bandage fibrinogen dosage study

The blood loss in the control group was 2819 ± 629 mL (mean \pm SEM) which was significantly greater than any of the treatment groups ($p < .05$).

Blood loss in the fibrin sealant bandage treatment groups did not differ significantly from each other. The volumes were 588 ± 629 mL, 632 ± 703 mL, and 758 ± 629 mL in the 15, 8, and 4mg fibrinogen / cm² groups, respectively.

The total fluid resuscitation volume was 2757 ± 565 mL, 1448 ± 505 mL, 1775 ± 505 mL, and 2208 ± 565 mL for the control, 15mg, 8mg, and 4mg fibrinogen / cm² groups, respectively. The fibrinogen and all CBC components decreased as the blood loss increased. PT and PTT increased.

Some of the clots from the fibrin sealant bandages used in the pigs were examined: 3/3 control bandages did not adhere, 3/3 in the 15mg/cm² bandage group adhered well, 3/3 in the 8mg/cm² bandage group adhered, and 3/3 in the 4mg/cm² bandage group adhered slightly. One pig died prior to 60 minutes in each of the control, 4mg, and 8mg treatment groups. All of the animals survived to 60 minutes in the 15mg group. This study confirms the previous finding that the fibrin sealant bandage decreases blood loss following Grade V liver injury in swine.

The data suggest that fibrinogen levels from 4mg to 15mg/cm² are effective for hemorrhage control. Based on assessments of the clot quality, it appears that fibrinogen dose is related to quality. The higher dose is associated with more firm and tightly adhered clots. While lower fibrinogen doses

are effective for hemorrhage control during the initial 60 minutes, longer term survival will likely depend on clot quality. Future survival studies will focus on determining the amount of fibrinogen that produces both short term (60 min) and longer term hemostasis and survival.

WHAT IS CLAIMED IS:

1. A hemostatic sandwich bandage for treating wounded tissue in a patient which comprises:

- (i) a first fibrinogen layer;
- 5 (ii) a thrombin layer adjacent to said first fibrinogen layer; and
- (iii) a second fibrinogen layer adjacent to said thrombin layer.

2. A hemostatic sandwich bandage for treating wounded tissue in a patient which comprises:

- (i) a resorbable material layer;
- 10 (ii) a first fibrinogen layer adjacent to said resorbable material layer;
- (iii) a thrombin layer adjacent to said first fibrinogen layer; and
- (iv) a second fibrinogen layer adjacent to said thrombin layer.

3. A hemostatic sandwich bandage for treating wounded tissue in a patient which comprises:

- 15 (i) a first fibrinogen layer;
- (ii) a resorbable material layer adjacent to said first fibrinogen layer;
- (iii) a thrombin layer adjacent to said resorbable material layer; and
- (iv) a second fibrinogen layer adjacent to said thrombin layer.

4. A hemostatic sandwich bandage for treating wounded tissue in a patient which
20 comprises:

- (i) a resorbable material layer; and

(iv) a thrombin layer adjacent to said resorbable material layer.

5. A hemostatic sandwich bandage for treating wounded in a patient which comprises:

(i) a first resorbable material layer;

(ii) a second resorbable material layer adjacent to said first resorbable material layer; and

5 (iii) a thrombin layer adjacent to said second resorbable material layer.

6. The hemostatic bandage according to any one of claims 1-5, further comprising a backing material.

7. The hemostatic sandwich bandage according to claim 4 or 5, wherein said resorbable material layer further contains fibrinogen.

10 8. The hemostatic sandwich bandage according to any one of claims 2-5, wherein said resorbable material is selected from the group consisting of glycolic acid polymers, lactic acid polymers and glycolic acid/lactic acid co-polymers.

9. The hemostatic sandwich bandage according to any one of claims 1-5, wherein one or more of said layers contains a solubilizing agent.

15 10. The hemostatic sandwich bandage according to any one of claims 1-5, wherein one or more of said layers contains a filler.

11. The hemostatic sandwich bandage according to any one of claims 1-5, wherein one or more of said layers contains a binding agent.

12. A method of treating wounded tissue, which comprises applying to said wounded tissue a hemostatic sandwich bandage according to any one of claims 1-5.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10952

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L15/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 606 337 A (ZIMMERMANN EBERHARD ET AL) 19 August 1986 (1986-08-19) abstract claims 1,6,9,10,14,28	1-12
X	US 5 702 715 A (NIKOLAYCHIK VICTOR V ET AL) 30 December 1997 (1997-12-30) figure 1C claim 14	1-12
X	EP 0 090 997 A (RUHLAND NACHF GMBH DR) 12 October 1983 (1983-10-12) column 2, line 28 - line 65	1-12
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 September 1999

Date of mailing of the international search report

17/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Muñoz, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10952

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 28832 A (NEW GENERATION MEDICAL CORP ;KOSOW DAVID P (US)) 14 August 1997 (1997-08-14) abstract page 4, paragraph 1 page 11, paragraph 1 - paragraph 2 ---	1,6,8-12
A	HOLCOMB J.B. ET AL.: "Implications of new dry fibrin sealant technology for trauma surgery" SURGICAL CLINICS OF NORTH AMERICA, vol. 77, no. 4, 1997, pages 943-950, XP002113927 -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/10952

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1 (iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10952

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4606337	A	19-08-1986	DE 3214337 A	27-10-1983
			AT 38937 T	15-12-1988
			DE 3378562 A	05-01-1989
			EP 0092200 A	26-10-1983
			US 4683142 A	28-07-1987
US 5702715	A	30-12-1997	WO 9715188 A	01-05-1997
EP 0090997	A	12-10-1983	DE 3212412 A	13-10-1983
			AT 47317 T	15-11-1989
			JP 1636531 C	31-01-1992
			JP 2060339 B	17-12-1990
			JP 58185162 A	28-10-1983
WO 9728832	A	14-08-1997	CA 2245585 A	14-08-1997